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Cystic fibrosis are at risk of colonization by a number of fungi, including
Geosmithiaargillacea which appears to be an emerging pathogen in these patients. This
pathogen has been recently reported as a cause of invasive/systemic mycosis in
immunocompromized patients such as colonized patients who are immunosuppressed
for lung transplantation. In this context, we report here a case of clinical and
microbiological efficacy of micafungin in a French cystic fibrosis patient chronically
colonized with G. argillacea. O.D., a female F508Del-CFTR homozygous patient was
diagnosed at birth with cystic fibrosis in January 1996. She was found chronically
colonised with multi-resistant Staphylococcus aureus (MRSA) from 1997 to 2011, and
with Aspergillus fumigatus from 2001 to 2006. She was treated alternatively with oral
voriconazole and itraconazole from 2004 to 2008, and with posaconazole since february
2008. Geosmithia argillacea was first diagnosed in May 2007, and chronic colonisation
was persistent from this date to August 2010 with 23/28 fungus positive sputum
samples, in spite of posaconazole therapy. For an isolate obtained in October 2008,
minimal inhibitory/effective concentrations (MIC/MEC, mg/ml) determined using the
Eucast method were 2.0, 2.0, 16.0, 2,0, 0.25 and 0.015 for amphotericin B,
itraconazole, voriconazole, posaconazole, caspofungin and micafungin, respectively.
The FEV1 predicted value was 73% at the time of first fungus isolation and was
decreased to 47% in October 2009. She then was given caspofungin for 21 days ((70
mg/day, later reduced to 50 mg) which resulted in clinical improvement (FEV1 = 64%
in January 2010) without eradication of G. argillacea. In June 2010, treatment with
micafungin (75 mg, 21days) was realized owing to deterioration of the respiratory
function (FEV1 = 56%),without clinical improvement ( FEV1 = 47% in August 2010).
O.D. was then treated from September, 23 to November 3, 2010 with micafungin
(100mg bid for 21 days and 100mg/day for the following 21 days) which resulted in
clinical and microbiological improvement. FEV1 predicted ranged 67-68% in October
and December 2010, and February and May 2011, and from the end of treatment to
December 2010, 5/6 sputum samples were found negative for G. argillacea. The
positive sample contained fungus of the same genotype as previous isolates. The
present case is to our knowledge the first description of G. argillacea eradication in a
chronically colonized cystic fibrosis patient. Similar to previous studies, G. argillacea
colonization was detected in the presence of chronic MRSA after A. fumigatus
eradication. Since no change in bacterial colonization was observed before, during, and
after G. argillacea colonization, the present case is consistent with a pathogenic role of
the fungus in cystic fibrosis patients. In vitro antifungal susceptibility assays suggested
that echinocandins are most effective agents against this fungus with a lowest MEC for
micafungin (7 isolates studied, MEC range: 0.015-0.03), although eradication could
only be obtained with high dose micafungin for a long time (6 weeks).
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